Open Access Open Access  Restricted Access Subscription Access

Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: 131I-antiAFPMcAb-GCV-BSA-NPs


Affiliations
1 Clinical Medical Institute, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China
2 Medical School, Southeast University, Nanjing, Jiangsu 210009, China
3 Key Laboratory of Advanced Catalytic Material and Technology, Changzhou University, Changzhou, Jiangsu 213000, China
 

An effective strategy has been developed for synthesis of radionuclide immune albumin nanospheres (131I-antiAFPMcAb-GCVBSA- NPs). In vitro as well as in vivo targeting of 131I-antiAFPMcAb-GCV-BSA-NPs to AFP-positive hepatoma was examined. In cultured HepG2 cells, the uptake and retention rates of 131I-antiAFPMcAb-GCV-BSA-NPs were remarkably higher than those of 131I alone. As well, the uptake rate and retention ratios of 131I-antiAFPMcAb-GCV-BSA-NPs in AFP-positive HepG2 cells were also significantly higher than those in AFP-negative HEK293 cells. Compared to 131I alone, 131I-antiAFPMcAb-GCV-BSA-NPs were much more easily taken in and retained by hepatoma tissue, with a much higher T/NT. Due to good drug-loading, high encapsulation ratio, and highly selective affinity for AFP-positive tumors, the 131I-antiAFPMcAb-GCV-BSA-NPs are promising for further effective radiation-gene therapy of hepatoma.
User
Notifications
Font Size

Abstract Views: 113

PDF Views: 25




  • Hepatoma-Targeted Radionuclide Immune Albumin Nanospheres: 131I-antiAFPMcAb-GCV-BSA-NPs

Abstract Views: 113  |  PDF Views: 25

Authors

Mei Lin
Clinical Medical Institute, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China
Junxing Huang
Clinical Medical Institute, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China
Dongsheng Zhang
Medical School, Southeast University, Nanjing, Jiangsu 210009, China
Xingmao Jiang
Key Laboratory of Advanced Catalytic Material and Technology, Changzhou University, Changzhou, Jiangsu 213000, China
Jia Zhang
Medical School, Southeast University, Nanjing, Jiangsu 210009, China
Hong Yu
Clinical Medical Institute, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China
Yanhong Xiao
Clinical Medical Institute, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China
Yujuan Shi
Clinical Medical Institute, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China
Ting Guo
Clinical Medical Institute, Taizhou People’s Hospital Affiliated to Nantong University, Taizhou, Jiangsu 225300, China

Abstract


An effective strategy has been developed for synthesis of radionuclide immune albumin nanospheres (131I-antiAFPMcAb-GCVBSA- NPs). In vitro as well as in vivo targeting of 131I-antiAFPMcAb-GCV-BSA-NPs to AFP-positive hepatoma was examined. In cultured HepG2 cells, the uptake and retention rates of 131I-antiAFPMcAb-GCV-BSA-NPs were remarkably higher than those of 131I alone. As well, the uptake rate and retention ratios of 131I-antiAFPMcAb-GCV-BSA-NPs in AFP-positive HepG2 cells were also significantly higher than those in AFP-negative HEK293 cells. Compared to 131I alone, 131I-antiAFPMcAb-GCV-BSA-NPs were much more easily taken in and retained by hepatoma tissue, with a much higher T/NT. Due to good drug-loading, high encapsulation ratio, and highly selective affinity for AFP-positive tumors, the 131I-antiAFPMcAb-GCV-BSA-NPs are promising for further effective radiation-gene therapy of hepatoma.